BioPlus Specialty Pharmacy Works to Raise Awareness to Hepatitis C

Date: 2/24/2010

Posters aim to remind people to get tested.

Altamonte Springs, FL. Feb 15th 2010 BioPlus Specialty Pharmacy today announced the
launch of their campaign to raise awareness of Hepatitis C (HCV). “There just isn’t enough
attention drawn to Hepatitis,” said Enoch Strollo, VP of BioPlus. “Without media exposure,
thousands to millions of people are walking around infected with HCV without obvious
symptoms, and with no knowledge of having the disease. Media exposure will change this.
There are several medicines currently available and several more in clinical development that show great promise in treating HCV, so now is the best time to remind people to get tested.”

Most recently Three Rivers Pharmaceuticals received approval for RibaPak®, a higher dose per pill form of ribavirin. This formulation makes adherence easier by allowing patients to take only two pills per day instead of up to six. “The pharmaceutical world is eagerly anticipating the approval of protease inhibitors to be added to current HCV therapies that will increase the chance of a successful outcome ‐ viral remission” Enoch continued. The protease inhibitors that are on the radar are Telaprevir from Vertex Pharamceuticals (NYSE: VRTX) and Boceprevir from Merck, formerly Schering Plough (NYSE: MRK)

“There has never been enough awareness regarding HCV,” said Dr. Stephen Vogt, PharmD and CEO of BioPlus. “In the 20 years we have been working with chronic diseases, the therapies for HCV are the most challenging to manage. Confidence in the treatments, understanding how the disease spreads and information on how to protect oneself is limited. With this lack of education and awareness comes a complacent attitude towards getting tested. In addition, even when diagnosed, there is no sense of urgency in getting treatment.”

The posters are being provided at no charge through the company web site:
www.bioplusrx.com. They are also being proactively sent out to hospitals and doctor offices
across the country.

Hepatitis RX Assist®

The Hepatitis RX Assist program was designed to eliminate all of the issues related to Hepatitis treatment. As the pioneers of Specialty Pharmacy, BioPlus has been building the framework of this program for years.

Highlights of the program include:

• Educational information regarding the disease and the possible treatments.
• Insurance verification and authorization assistance to help ensure coverage.
• Working collaboratively with Pharmaceutical Manufacturer financial programs for
patients who are uninsured.
• Financial aid programs for the underinsured.
• 24 hour a day 7 day a week access to specialized Doctors of Pharmacy.
• Nurse teaching on self administration of medications.
• Patient / Therapy specific plan which ensures compliance rates >35% higher than
national average.
• Greater chance at a successful completion of therapy.
• Significant overall treatment savings to managed care.

About BioPlus Specialty Pharmacy Services, Inc

BioPlus continues to pioneer Specialty Pharmacy by managing therapies and improving
outcomes. Our patient and therapy specific care plans ensure the best opportunity of achieving a successful outcome.

As the largest independent Specialty Pharmacy, BioPlus is able to remain focused on the
mission of changing the way that chronic diseases are managed. With the ability to show the
true value of compliance and adherence, BioPlus’ Therapy Management programs are
eliminating the managed care costs, which are nearing 300 MILLION dollars annually related to non compliance.

For more information, go to www.bioplusrx.com

This press release contains "forward‐looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forwardlooking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward‐looking statement, whether as a result of new information, future events, or otherwise. Forward‐looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business.